Anterior eye segment drug delivery systems: Current treatments and future challenges

Journal of Ocular Pharmacology and Therapeutics

Volumn 29, Issue 2, 2013, Pages 92-105

  Molokhia, Sarah A ^a   Thomas, Samuel C ^a   Garff, Kevin J ^a   Mandell, Kenneth J ^b   Wirostko, Barbara M ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACIONT; AGENTS ACTING ON THE EYE; AMINO ACID; ANTIHISTAMINIC AGENT; ARTIFICIAL TEAR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CATION; CORTICOSTEROID; CYCLOSPORIN; DEXAMETHASONE; EGP 437; EYE DROPS; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; KETOTIFEN FUMARATE; LACISERT; LATANOPROST; MACROGOL; MULTIDRUG RESISTANCE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEOSIDE; PILOCARPINE; POLY(METHYL METHACRYLATE); PROSTAGLANDIN DERIVATIVE; STEROID; TODDD; UNCLASSIFIED DRUG; VASOCONSTRICTOR AGENT; ZONULA OCCLUDENS PROTEIN;

ALLERGIC CONJUNCTIVITIS; AMNION; ANTERIOR EYE SEGMENT; BLURRED VISION; BRADYCARDIA; CATARACT; CATARACT EXTRACTION; CELL MEMBRANE; CLINICAL TRIAL (TOPIC); CONJUNCTIVA; CONJUNCTIVAL HYPEREMIA; CONTACT LENS; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRY EYE; EYE DISEASE; EYE INFLAMMATION; EYE IRRITATION; EYELID EDEMA; FOREIGN BODY REACTION; GAP JUNCTION; GEL; GLAUCOMA; HUMAN; HYPEREMIA; HYPERSENSITIVITY; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; INTRAOCULAR PRESSURE ABNORMALITY; IONTOPHORESIS; IRITIS; LIPOPHILICITY; LIQUID; MEDICAL DEVICE; MICROELECTROMECHANICAL SYSTEM; NONHUMAN; OINTMENT; PATIENT COMPLIANCE; PHOTOPHOBIA; POSTOPERATIVE INFLAMMATION; PUNCTAL PLUG; RABBIT; RECTOUTERINE POUCH; REVIEW; SILICONE PROSTHESIS; SUSPENSION; TRABECULAR MESHWORK;

ANIMALS; ANTERIOR EYE SEGMENT; BIOLOGICAL AVAILABILITY; CORNEA; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; EYE DISEASES; FORECASTING; HUMANS; PHARMACEUTICAL PREPARATIONS; TREATMENT OUTCOME;

EID: 84875041196     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2012.0241     Document Type: Review

References (120)

1. Dey, S., Anand, B.S., Patel, J., & Mitra, A.K. Transporters/ receptors in the anterior chamber: pathways to explore ocular drug delivery strategies. Expert Opin. Biol. Ther. 3:23-44, 2003.
2. Majumdar, S., Tirucherai, G.S., Pal, D., & Mitra, A.K. Functional differences in nucleoside and nucleobase transporters expressed on the rabbit corneal epithelial cell line (SIRC) and isolated rabbit cornea. AAPS PharmSci. 5:E15, 2003.
3. Saha, P., Yang, J.J., & Lee, V.H. Existence of a p-glycoprotein drug efflux pump in cultured rabbit conjunctival epithelial cells. Invest. Ophthalmol. Vis. Sci. 39:1221-1226, 1998.
4. Ito, A., Yamaguchi, K., Tomita, H., Suzuki, T., Onogawa, T., Sato, T., Mizutamari, H., Mikkaichi, T., Nishio, T., Unno, M., Sasano, H., Abe, T., & Tamai, M. Distribution of rat organic anion transporting polypeptide-E (oatp-E) in the rat eye. Invest. Ophthalmol. Vis. Sci. 44:4877-4884, 2003.
5. Ueda, H., Horibe, Y., Kim, K.J., & Lee, V.H. Functional characterization of organic cation drug transport in the pigmented rabbit conjunctiva. Invest. Ophthalmol. Vis. Sci. 41:870-876, 2000.
6. Gaudana, R., Ananthula, H.K., Parenky, A., & Mitra, A.K. Ocular drug delivery. AAPS J. 12:348-360, 2010.
7. Raghava, S., Hammond, M., & Kompella, U.B. Periocular routes for retinal drug delivery. Expert Opin. Drug Deliv. 1:99-114, 2004.
8. Liu, X., Li, S.K., & Jeong, E.K. Ocular pharmacokinetic study of a corticosteroid by 19F MR. Exp. Eye Res. 91:347-352, 2010.
9. Urtti, A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv. Drug Deliv. Rev. 58:1131-1135, 2006.
10. Thassu, D., & Chader, G. Ocular Drug Delivery Systems: Barriers and Application of Nanoparticulate Systems. Boca Raton: CRC Press/Taylor & Francis; 2013.
11. Molokhia, S.A., Jeong, E.K., Higuchi, W.I., & Li, S.K. Examination of barriers and barrier alteration in transscleral iontophoresis. J. Pharm. Sci. 97:831-844, 2008.
12. Kim, S.H., Csaky, K.G., Wang, N.S., & Lutz, R.J. Drug elimination kinetics following subconjunctival injection using dynamic contrast-enhanced magnetic resonance imaging. Pharm. Res. 25:512-520, 2008.
13. Lee, S.J., He, W., Robinson, S.B., Robinson, M.R., Csaky, K.G., & Kim, H. Evaluation of clearance mechanisms with transscleral drug delivery. Invest. Ophthalmol. Vis. Sci. 51:5205-5212, 2010.
14. Tombran-Tink, J., & Barnstable, C.J. Ocular Transporters in Ophthalmic Diseases and Drug Delivery. Totowa, NJ: Humana Press; 2008.
15. Diecke, F.P., Cacace, V.I., Montalbetti, N., Ma, L., Kuang, K., Iserovich, P., & Fischbarg, J. Comparative permeabilities of the paracellular and transcellular pathways of corneal endothelial layers. J. Membr. Biol. 242:41-51, 2011.
16. Fischbarg, J., Diecke, F.P., Iserovich, P., & Rubashkin, A. The role of the tight junction in paracellular fluid transport across corneal endothelium. Electro-osmosis as a driving force. J. Membr. Biol. 210:117-130, 2006.
17. Barocas, V.H., & Balachandran, R.K. Sustained transscleral drug delivery. Expert Opin. Drug Deliv. 5:1-10, 2008.
18. Raviola, G., Sagaties, M.J., & Miller, C. Intercellular junctions between fibroblasts in connective tissues of the eye of macaque monkeys. A thin section and freeze fracture analysis. Invest. Ophthalmol. Vis. Sci. 28:834-841, 1987.
19. Benson, H. Permeability of the cornea to topically applied drugs. Arch. Ophthalmol. 91:313-327, 1974.
20. Chen, W., Li, Z., Hu, J., Zhang, Z., Chen, L., Chen, Y., and Liu, Z. Corneal alternations induced by topical application of benzalkonium chloride in rabbit. PloS One. 6:e26103, 2011.
21. Gobbels, M., & Spitznas, M. Corneal epithelial permeability of dry eyes before and after treatment with artificial tears. Ophthalmology. 99:873-878, 1992.
22. Ahmed, I., & Patton, T.F. Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Invest. Ophthalmol. Vis. Sci. 26:584-587, 1985.
23. Lee, V.H., & Robinson, J.R. Mechanistic and quantitative evaluation of precorneal pilocarpine disposition in albino rabbits. J. Pharm. Sci. 68:673-684, 1979.
24. Hamalainen, K.M., Kananen, K., Auriola, S., Kontturi, K., and Urtti, A. Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera. Invest. Ophthalmol. Vis. Sci. 38:627-634, 1997.
25. Fishburn, C.S. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J. Pharm. Sci. 97:4167-4183, 2008.
26. Kuno, N., & Fujii, S. Recent advances in ocular drug delivery systems. Polymers. 3:193-221, 2011.
27. Olsen, T.W., Edelhauser, H.F., Lim, J.I., & Geroski, D.H. Human scleral permeability. Effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest. Ophthalmol. Vis. Sci. 36:1893-1903, 1995.
28. Olsen, T.W., Aaberg, S.Y., Geroski, D.H., & Edelhauser, H.F. Human sclera: thickness and surface area. Am. J. Ophthalmol. 125:237-241, 1998.
29. Dunlevy, J.R., & Rada, J.A. Interaction of lumican with aggrecan in the aging human sclera. Invest. Ophthalmol. Vis. Sci. 45:3849-3856, 2004.
30. Kim, S.H., Lutz, R.J., Wang, N.S., & Robinson, M.R. Transport barriers in transscleral drug delivery for retinal diseases. Ophthalmic Res. 39:244-254, 2007.
31. Cruysberg, L.P., Nuijts, R.M., Geroski, D.H., Koole, L.H., Hendrikse, F., & Edelhauser, H.F. In vitro human scleral permeability of fluorescein, dexamethasone-fluorescein, methotrexate-fluorescein and rhodamine 6G and the use of a coated coil as a new drug delivery system. J. Ocul. Pharmacol. Ther. 18:559-569, 2002.
32. Nicoli, S., Ferrari, G., Quarta, M., Macaluso, C., Govoni, P., Dallatana, D., & Santi, P. Porcine sclera as a model of human sclera for in vitro transport experiments: histology, SEM, and comparative permeability. Mol. Vis. 15:259-266, 2009.
33. Ambati, J., Gragoudas, E.S., Miller, J.W., You, T.T., Miyamoto, K., Delori, F.C., & Adamis, A.P. Transscleral delivery of bioactive protein to the choroid and retina. Invest. Ophthalmol. Vis. Sci. 41:1186-1191, 2000.
34. Gaudana, R., Jwala, J., Boddu, S.H., & Mitra, A.K. Recent perspectives in ocular drug delivery. Pharm. Res. 26:1197-1216, 2009.
35. Mannermaa, E., Vellonen, K.S., & Urtti, A. Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics. Adv. Drug Deliv. Rev. 58:1136-1163, 2006.
36. Cassin, B., Solomon, S., & Rubin, M.L. Dictionary of Eye Terminology. Gainesville, Fla.: Triad Pub. Co.; 1990.
37. Herrero-Vanrell, R., & Peral, A. [International Dry Eye Workshop (DEWS). Update of the disease]. Arch. de la Sociedad Espanola de Oftalmologia. 82:733-734, 2007.
38. Moss, S.E., Klein, R., & Klein, B.E. Prevalence of and risk factors for dry eye syndrome. Arch. Ophthalmol. 118:1264-1268, 2000.
39. Latkany, R. Dry eyes: etiology and management. Curr. Opin. Ophthalmol. 19:287-291, 2008.
40. Taylor, S.A., Galbraith, S.M., & Mills, R.P. Causes of noncompliance with drug regimens in glaucoma patients: a qualitative study. J. Ocul. Pharmacol. Ther. 18:401-409, 2002.
41. Allansmith, M.R., & Ross, R.N. Ocular allergy. Clin. Allergy. 18:1-13, 1988.
42. Tarabishy, A.B., & Jeng, B.H. Bacterial conjunctivitis: a review for internists. Cleve. Clin. J. Med. 75:507-512, 2008.
43. Butrus, S., & Portela, R. Ocular allergy: diagnosis and treatment. Ophthalmol. Clin. North Am. 18:485-492, v, 2005.
44. Bielory, L. Update on ocular allergy treatment. Expert Opin. Pharmacother. 3:541-553, 2002.
45. Taravati, P., Lam, D.L., Leveque, T., & Van Gelder, R.N. Postcataract surgical inflammation. Curr. Opin. Ophthalmol. 23:12-18, 2012.
46. Al-Mezaine, H.S., Kangave, D., Al-Assiri, A., & Al-Rajhi, A.A. Acute-onset nosocomial endophthalmitis after cataract surgery: incidence, clinical features, causative organisms, and visual outcomes. J. Cataract Refract. Surg. 35:643-649, 2009.
47. Apple, D.J., Solomon, K.D., Tetz, M.R., Assia, E.I., Holland, E.Y., Legler, U.F., Tsai, J.C., Castaneda, V.E., Hoggatt, J.P., and Kostick, A.M. Posterior capsule opacification. Surv. Ophthalmol. 37:73-116, 1992.
48. Miyake, K., Maekubo, K., Miyake, Y., & Nishi, O. Pupillary fibrin membrane. A frequent early complication after posterior chamber lens implantation in Japan. Ophthalmology. 96:1228-1233, 1989.
49. Weiss, K., Steinbrugger, I., Weger, M., Ardjomand, N., Maier, R., Wegscheider, B.J., Wedrich, A., & El-Shabrawi, Y. Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab. Eye (Lond). 23:1812-1818, 2009.
50. DeCroos, F.C., & Afshari, N.A. Perioperative antibiotics and anti-inflammatory agents in cataract surgery. Curr. Opin. Ophthalmol. 19:22-26, 2008.
51. Quigley, H.A. Glaucoma. Lancet. 377:1367-1377, 2011.
52. Cedrone, C., Mancino, R., Cerulli, A., Cesareo, M., and Nucci, C. Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects. Prog. Brain Res. 173:3-14, 2008.
53. Musch, D.C., Gillespie, B.W., Niziol, L.M., Lichter, P.R., and Varma, R. Intraocular pressure control and long-term visual field loss in the Collaborative Initial Glaucoma Treatment Study. Ophthalmology. 118:1766-1773, 2011.
54. Rein, D.B., Zhang, P., Wirth, K.E., Lee, P.P., Hoerger, T.J., McCall, N., Klein, R., Tielsch, J.M., Vijan, S., & Saaddine, J. The economic burden of major adult visual disorders in the United States. Arch. Ophthalmol. 124:1754-1760, 2006.
55. Sleath, B., Blalock, S., Covert, D., Stone, J.L., Skinner, A.C., Muir, K., & Robin, A.L. The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity. Ophthalmology. 118:2398-2402, 2011.
56. Robin, A., & Grover, D.S. Compliance and adherence in glaucoma management. Indian J. Ophthalmol. 59 Suppl:S93-S96, 2011.
57. Tsai, J.C., McClure, C.A., Ramos, S.E., Schlundt, D.G., and Pichert, J.W. Compliance barriers in glaucoma: a systematic classification. J. Glaucoma. 12:393-398, 2003.
58. Tsai, J.C. Medication adherence in glaucoma: approaches for optimizing patient compliance. Curr. Opin. Ophthalmol. 17:190-195, 2006.
59. Karavellas, M.P., Song, M., Macdonald, J.C., & Freeman, W.R. Long-term posterior and anterior segment complications of immune recovery uveitis associated with cytomegalovirus retinitis. Am. J. Ophthalmol. 130:57-64, 2000.
60. Chen, C.S., Roberton, D., & Hammerton, M.E. Juvenile arthritis-Associated uveitis: visual outcomes and prognosis. Can. J. Ophthalmol. 39:614-620, 2004.
61. Walt, J.G., Wilensky, J.T., Fiscella, R., Chiang, T.H., and Guckian, A. Refill rates and budget impact of glaucoma lipid therapy: a retrospective database analysis. Clin. Drug Invest. 27:819-825, 2007.
62. Hennessy, A.L., Katz, J., Covert, D., Kelly, C.A., Suan, E.P., Speicher, M.A., Sund, N.J., & Robin, A.L. A video study of drop instillation in both glaucoma and retina patients with visual impairment. Am. J. Ophthalmol. 152:982-988, 2011.
63. Robin, A.L., Novack, G.D., Covert, D.W., Crockett, R.S., and Marcic, T.S. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am. J. Ophthalmol. 144:533-540, 2007.
64. Hennessy, A.L., Katz, J., Covert, D., Protzko, C., and Robin, A.L. Videotaped evaluation of eyedrop instillation in glaucoma patients with visual impairment or moderate to severe visual field loss. Ophthalmology. 117:2345-2352, 2010.
65. Beckers, H.J., Schouten, J.S., Webers, C.A., van der Valk, R., and Hendrikse, F. Side effects of commonly used glaucoma medications: comparison of tolerability, chance of discontinuation, and patient satisfaction. Graefe's Arch. Clin. Exp. Ophthalmol. 246:1485-1490, 2008.
66. Zimmerman, T.J. Topical ophthalmic beta blockers: a comparative review. J. Ocul. Pharm. 9:373-384, 1993.
67. Servat, J.J., & Bernardino, C.R. Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue. Drugs Aging. 28:267-282, 2011.
68. Pflugfelder, S.C. Tear dysfunction and the cornea: LXVIII Edward Jackson Memorial Lecture. Am. J. Ophthalmol. 152:900-909 e901, 2011.
69. Skalicky, S.E., Goldberg, I., & McCluskey, P. Ocular surface disease and quality of life in patients with glaucoma. Am. J. Ophthalmol. 153:1-9 e2, 2012.
70. Bodor, N., & Buchwald, P. Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems. AAPS J. 7:E820-E833, 2005.
71. Urtti, A., & Salminen, L. Minimizing systemic absorption of topically administered ophthalmic drugs. Surv. Ophthalmol. 37:435-456, 1993.
72. Short, B.G. Safety evaluation of ocular drug delivery formulations: techniques and practical considerations. Toxicol. Pathol. 36:49-62, 2008.
73. Sultana, Y., Jain, R., Aqil, M., & Ali, A. Review of ocular drug delivery. Curr. Drug Deliv. 3:207-217, 2006.
74. Sjoquist, B., & Stjernschantz, J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv. Ophthalmol. 47 Suppl 1:S6-S12, 2002.
75. Davis, J.L., Gilger, B.C., & Robinson, M.R. Novel approaches to ocular drug delivery. Curr. Opin. Mol. Ther. 6:195-205, 2004.
76. Leahy CD, E.E., Ellis, J.Y., & Crawford, K.S. Efficacy of a Topical Ocular Drug Delivery Device (TODDD) for the treatment of glaucoma by telemetric measurement of IOP in the normal rabbit. ARVO Meeting Abstracts. Fort Lauderdale, Florida; 2007; p. 5816.
77. McDonald, M., D'Aversa, G., Perry, H.D., Wittpenn, J.R., Donnenfeld, E.D., & Nelinson, D.S. Hydroxypropyl cellulose ophthalmic inserts (lacrisert) reduce the signs and symptoms of dry eye syndrome and improve patient quality of life. Trans. Am. Ophthalmol. Soc. 107:214-221, 2009.
78. Nguyen, T., & Latkany, R. Review of hydroxypropyl cellulose ophthalmic inserts for treatment of dry eye. Clin. Ophthalmol. 5:587-591, 2011.
79. Kongnara Papangkorn, D.M., Charlotte Butler, David J. Knauss, John W. Higuchi, Balbir Brar, and William I. Higuchi. A topical ocular toxicity study of dexamethasone sodium phosphate formulations administered with visulex-p in rabbits. ARVO Meeting Abstracts. Fort Lauderdale, Florida; 2012; p. 478.
80. Kompella, U.B., Kadam, R.S., & Lee, V.H. Recent advances in ophthalmic drug delivery. Ther. Deliv. 1:435-456, 2010.
81. Chee, S.P. Moxifloxacin punctum plug for sustained drug delivery. J. Ocul. Pharmacol. Ther. 28:340-349, 2011.
82. Lee, S.S., Hughes, P., Ross, A.D., & Robinson, M.R. Biodegradable implants for sustained drug release in the eye. Pharm. Res. 27:2043-2053, 2010.
83. Tan, D.T., Chee, S.P., Lim, L., & Lim, A.S. Randomized clinical trial of a new dexamethasone delivery system (Surodex) for treatment of post-cataract surgery inflammation. Ophthalmology. 106:223-231, 1999.
84. Hillman, J.S. Management of acute glaucoma with pilocarpine-soaked hydrophilic lens. Br. J. Ophthalmol. 58:674-679, 1974.
85. Karlgard, C.C., Wong, N.S., Jones, L.W., & Moresoli, C. In vitro uptake and release studies of ocular pharmaceutical agents by silicon-containing and p-HEMA hydrogel contact lens materials. Int. J. Pharm. 257:141-151, 2003.
86. Xu, J., Li, X., & Sun, F. In vitro and in vivo evaluation of ketotifen fumarate-loaded silicone hydrogel contact lenses for ocular drug delivery. Drug Deliv. 18:150-158, 2011.
87. Bucolo, C., Mangiafico, S., & Spadaro, A. Methylprednisolone delivery by Hyalobend corneal shields and its effects on rabbit ocular inflammation. J. Ocul. Pharmacol. Ther. 12:141-149, 1996.
88. Gulsen, D., & Chauhan, A. Ophthalmic drug delivery through contact lenses. Invest. Ophthalmol. Vis. Sci. 45:2342-2347, 2004.
89. Ciolino, J.B., Hoare, T.R., Iwata, N.G., Behlau, I., Dohlman, C.H., Langer, R., & Kohane, D.S. A drug-eluting contact lens. Invest. Ophthalmol. Vis. Sci. 50:3346-3352, 2009.
90. Ciolino, J.B., Hudson, S.P., Mobbs, A.N., Hoare, T.R., Iwata, N.G., Fink, G.R., & Kohane, D.S. A prototype antifungal contact lens. Invest. Ophthalmol. Vis. Sci. 52:6286-6291, 2011.
91. Ali, M., Horikawa, S., Venkatesh, S., Saha, J., Hong, J.W., and Byrne, M.E. Zero-order therapeutic release from imprinted hydrogel contact lenses within in vitro physiological ocular tear flow. J. Control. Release. 124:154-162, 2007.
92. Tieppo, A., White, C.J., Paine, A.C., Voyles, M.L., McBride, M.K., & Byrne, M.E. Sustained in vivo release from imprinted therapeutic contact lenses. J. Control. Release. 157:391-397, 2011.
93. Dumbleton, K. Adverse events with silicone hydrogel continuous wear. Cont. Lens Anterior Eye. 25:137-146, 2002.
94. Siqueira, R.C., Filho, E.R., Fialho, S.L., Lucena, L.R., Filho, A.M., Haddad, A., Jorge, R., Scott, I.U., & Cunha Ada, S. Pharmacokinetic and toxicity investigations of a new intraocular lens with a dexamethasone drug delivery system: a pilot study. Ophthalmologica. 220:338-342, 2006.
95. Eperon, S., Bossy-Nobs, L., Petropoulos, I.K., Gurny, R., and Guex-Crosier, Y. A biodegradable drug delivery system for the treatment of postoperative inflammation. Int. J. Pharm. 352:240-247, 2008.
96. Shukla, A., Fuller, R.C., & Hammond, P.T. Design of multi-drug release coatings targeting infection and inflammation. J. Control. Release. 155:159-166, 2011.
97. Molokhia, S.A., Sant, H., Simonis, J., Bishop, C.J., Burr, R.M., Gale, B.K., & Ambati, B.K. The capsule drug device: novel approach for drug delivery to the eye. Vis. Res. 50:680-685, 2010.
98. Saati, S., Lo, R., Li, P.Y., Meng, E., Varma, R., & Humayun, M.S. Mini drug pump for ophthalmic use. Trans. Am. Ophthalmol. Soc. 107:60-70, 2009.
99. Avery, R.L., Saati, S., Journey, M., Caffey, S., Varma, R., Tai, Y.C., & Humayun, M.S. A novel implantable, refillable pump for intraocular drug delivery. ARVO 2010 Annual Meeting, Fort Lauderdale, Florida; 2010; p. 3799.
100. Azad Khan, M.Y., Mohd Asif, Iti Chauhan, Alok P. Singh, Rajat Sharma, Pradeep Singh, and Shubham Rai. Iontophoretic drug delivery: history and applications. J. Appl. Pharm. Sci. 1:11-24, 2011.
101. Misra, A. Challenges in Delivery of Therapeutic Genomics and Proteomics. Boston, MA: Elsevier; 2010.
102. Molokhia, S.A. Transscleral Iontophoresis. University of Utah, 2009.
103. Molokhia, S.A., Jeong, E.K., Higuchi, W.I., & Li, S.K. Examination of penetration routes and distribution of ionic permeants during and after transscleral iontophoresis with magnetic resonance imaging. Int. J. Pharm. 335:46-53, 2007.
104. Halhal, M., Renard, G., Courtois, Y., BenEzra, D., and Behar-Cohen, F. Iontophoresis: from the lab to the bed side. Exp. Eye Res. 78:751-757, 2004.
105. Cohen, A.E., Assang, C., Patane, M.A., From, S., & Korenfeld, M. Evaluation of dexamethasone phosphate delivered by ocular iontophoresis for treating noninfectious anterior uveitis. Ophthalmology. 119:66-73, 2012.
106. Vollmer, D.L., Szlek, M.A., Kolb, K., Lloyd, L.B., & Parkinson, T.M. In vivo transscleral iontophoresis of amikacin to rabbit eyes. J. Ocul. Pharmacol. Ther. 18:549-558, 2002.
107. Sarah, A., Molokhia, K.P., Donald Mix, Charlotte Butler, and Prasoona Karra, J.H., Balbir Brar, S., Kevin Li, William I. Higuchi. Transscleral iontophoretic delivery of Avastin- in vivo: drug distribution and safety aspects. In: 491/ D1168, ed. ARVO Meeting Abstracts. Fort Lauderdale, Florida; 2012.
108. Molokhia, S.A., Jeong, E.K., Higuchi, W.I., & Li, S.K. Transscleral iontophoretic and intravitreal delivery of a macromolecule: study of ocular distribution in vivo and postmortem with MRI. Exp. Eye Res. 88:418-425, 2009.
109. Chopra, P., Hao, J., & Li, S.K. Iontophoretic transport of charged macromolecules across human sclera. Int. J. Pharm. 388:107-113, 2010.
110. Nicoli, S., Ferrari, G., Quarta, M., Macaluso, C., & Santi, P. In vitro transscleral iontophoresis of high molecular weight neutral compounds. Eur. J. Pharm. Sci. 36:486-492, 2009.
111. Davies, J.B., Ciavatta, V.T., Boatright, J.H., & Nickerson, J.M. Delivery of several forms of DNA, DNA-RNA hybrids, and dyes across human sclera by electrical fields. Mol. Vis. 9:569-578, 2003.
112. Yoo, S.H., Dursun, D., Dubovy, S., Miller, D., Alfonso, E., Forster, R.K., Behar-Cohen, F., & Parel, J.M. Lontophoresis for the treatment of paecilomyces keratitis. Cornea. 21:131-132, 2002.
113. Patou, G. In vogue with venture. Nat. Biotechnol. 29:967-969, 2011.
114. Epstein, J.A. Politicizing NIH funding: a bridge to nowhere. J. Clin. Invest. 121:3362-3363, 2011.
115. Dvergsdal, E.Y., Lichtwark, H., Sanne, A.P., & Bolkan, H.A. The global health workforce crisis. Tidsskr. Nor. Laegeforen 131:2025-2028, 2011.
116. Sachdeva, A.K. Acquiring skills in new procedures and technology: the challenge and the opportunity. Arch. Surg. 140:387-389, 2005.
117. Hessel, F. Reimbursement for high-priced innovative medical devices in a DRG-based hospital care system: the German situation. Expert Rev. Pharmacoeconomics Outcomes Res. 5:377-381, 2005.
118. Mehta, S.S. Commercializing Successful Biomedical Technologies: Basic Principles for the Development of Drugs, Diagnostics and Devices. Cambridge, NY: Cambridge University Press; 2008.
119. Fattal, E., & Bochot, A. Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA. Adv. Drug Deliv. Rev. 58:1203-1223, 2006.
120. Montezuma, S.R., Vavvas, D., & Miller, J.W. Review of the ocular angiogenesis animal models. Semin. Ophthalmol. 24:52-61, 2009.